You are here

psoriasis

Amgen Submits Supplemental NDA for Mild-to-Moderate Psoriasis Drug Otezla

Amgen Submits Supplemental NDA for Mild-to-Moderate Psoriasis Drug Otezla

BioSpace

Flag link:

Dermavant shows deepening effects of tapinarof on psoriasis ahead of FDA filing

Dermavant shows deepening effects of tapinarof on psoriasis ahead of FDA filing

Fierce Biotech

Dermavant Sciences

clinical trials

Flag link:

DiCE gets its 'library' card ready as it speeds development of DNA database-derived molecules with more investor cash

DiCE gets its 'library' card ready as it speeds development of DNA database-derived molecules with more investor cash

Endpoints

small molecule drugs

Flag link:

Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis podcast

Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis podcast

Fierce Pharma

celebrity endorsements

Flag link:

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Pharmaforum

clinical trials

Flag link:

AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

Fierce Pharma

Flag link:

Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals

Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals

Fierce Pharma

Flag link:

UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market

UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market

Endpoints

Flag link:

Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA

Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA

Endpoints

Flag link:

Eli Lilly’s Mirikizumab Hits the Mark in Phase III Study, Bests Cosentyx

Eli Lilly’s Mirikizumab Hits the Mark in Phase III Study, Bests Cosentyx

BioSpace

clinical trials

Flag link:

Amgen's Enbrel Patents to Be Upheld Through 2029

Amgen's Enbrel Patents to Be Upheld Through 2029

Motley Fool

rheumatoid arthritis

Flag link:

UCB’s growth driver squares up against the competition

UCB’s growth driver squares up against the competition

EP Vantage

clinical trials

Flag link:

Amgen ramps up Otezla expansion effort with positive data in mild psoriasis

Amgen ramps up Otezla expansion effort with positive data in mild psoriasis

Fierce Pharma

Flag link:

Lilly spends big on mirikizumab

Lilly spends big on mirikizumab

EP Vantage

clinical trials

Flag link:

AbbVie Reports Successful Trial Results for Arthritis Drug

AbbVie Reports Successful Trial Results for Arthritis Drug

Motley Fool

clinical trials

Flag link:

AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis

AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis

Motley Fool

Boehringer Ingelheim

Flag link:

Durect shares rocked by midstage psoriasis flop, shifts focus to liver disease

Durect shares rocked by midstage psoriasis flop, shifts focus to liver disease

Fierce Biotech

clinical trials

Flag link:

UCB posts more supportive data from Humira rival bimekizumab

UCB posts more supportive data from Humira rival bimekizumab

Pharmaforum

Flag link:

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Fierce Pharma

Flag link:

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

Endpoints

clinical trials

Flag link:

Pages